放射性核素标记的成纤维细胞活化蛋白抑制剂在肿瘤诊疗一体化中的研究进展  

Research progress of radiolabeled fibroblast activation protein inhibitors in cancer radiotheranostics

作　　者：赵亮 林勤[2] 吴华[1] 陈皓鋆[1] Zhao Liang;Lin Qin;Wu Hua;Chen Haojun(Department of Nuclear Medicine,Minnan PET Center,the First Affiliated Hospital of Xiamen University,Xiamen 361003,China;Department of Radiation Oncology,the First Affiliated Hospital of Xiamen University,Xiamen 361003,China)

机构地区：[1]厦门大学附属第一医院核医学科,闽南PET中心,厦门361003 [2]厦门大学附属第一医院肿瘤放射治疗科,厦门361003

出　　处：《国际放射医学核医学杂志》2022年第10期629-634,共6页International Journal of Radiation Medicine and Nuclear Medicine

基　　金：国家自然科学基金(82071961)。

摘　　要：癌相关成纤维细胞(CAFs)是实体瘤肿瘤微环境中的重要成分之一。成纤维细胞活化蛋白(FAP)特异性高表达于CAFs,在大多数正常组织中不表达或低表达,是一种很有前景的肿瘤诊断与治疗靶点。近年来,放射性核素标记靶向FAP的分子探针在肿瘤的诊断和治疗中已取得一系列研究进展。笔者对FAP抑制剂(FAPI)新型分子影像探针在肿瘤诊断、辅助临床治疗决策优化及核素靶向治疗等方面进行综述,以期更深入地了解FAPI探针在核医学肿瘤诊疗中的临床应用价值。Cancer-associated fibroblasts(CAFs)are the essential components in the tumor microenvironment.Fibroblast activation protein(FAP)is a promising theranostic target because it is highly expressed in the CAFs of tumor stroma but lowly expressed in most of the normal tissue.Recently,a burst of studies reported the research progress of radiolabeled FAP-targeted molecular probe for tumor diagnosis as well as radionuclide therapy.For comprehensively understanding the clinical value of FAPI probe in tumoral nuclear medicine,this review summarizes the state-of-the-art of FAP inhibitors-based molecular imaging probe(FAPI)for cancer diagnosis,clinical therapeutic regimen improvement,and targeted radionuclide therapy.

关 键 词：癌相关成纤维细胞 放射性同位素 肿瘤 成纤维细胞活化蛋白抑制剂 

分 类 号：R730.44[医药卫生—肿瘤]